Auxly Cannabis Group Inc.

TSX:XLY.TO

Drug Manufacturers - Specialty & Generic

Healthcare
$3.53 +0.00%

+$0.00 today

Market cap
$364.42M
Beta
1.16
P/E (TTM)
7.3
EPS (TTM)
$0.02
52W Low $0.08High $0.19

Volume 0.13M

Average 0.71M

XLY.TO Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

Auxly Cannabis Group Inc.TSX: XLY.TO

Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026

Stock-based compensation dips below year-ago levels

Q1 FY2026 stock-based compensation of CA$1.01M fell 31.0% year over year, behind the +5.0% change in trailing-twelve-month stock-based compensation. Sequentially, it fell 31.6% from the prior quarter. Over 3 fiscal years it compounded at +9.4% a year.

Context

  • Stock-based compensation amounted to 3.5% of revenue in FY2025, down 0.6 pp from a year earlier.
  • Stock-based compensation increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -31.0% toward the trailing-twelve-month pace of +5.0%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
CA$1.01M-31.6% QoQ
Last fiscal yearDec 2025
CA$5.27M+4.4% YoY
LTMMar 2026
CA$4.81M+5.0% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-31.0%——
1 year+4.4%——
3-year CAGR+9.4%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

CAD · from the cash flow

Latest · FY2025
5.27M CAD
Year-over-year change
+4.4%
4-year CAGR
+38.4%

Stock-Based Compensation vs competitors

How XLY.TO compares with its peers on the latest reported figures

  • Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +5.0% is the highest of 4, against a peer median of -30.3%.
  • Stock-based compensation amounts to 3.0% of revenue for XLY.TO, versus a peer median of 1.6%.
XLY.TO Competitors
Stock-Based Compensation for XLY.TO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CRDL.TOCardiol Therapeutics Inc.LTM Mar 2026CA$11.4M CAD-21.5%+28.8%—
XLY.TOAuxly Cannabis Group Inc.LTM Mar 2026CA$4.81M CAD+5.0%+9.4%3.0%
CRRX.TOCareRx CorporationLTM Mar 2026CA$2.25M CAD-37.4%-15.9%0.6%
HLS.TOHLS Therapeutics Inc.LTM Mar 2026$1.4M USD-30.3%-13.2%2.5%
Peer median (excluding XLY.TO) —-30.3%-13.2%1.6%

Competitors are the stored peer set for XLY.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

CAD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(45.91M)(130.29M)(44.51M)(16.35M)41.86M
Depreciation & Amortization14.27M21.58M11.21M10.28M11.45M
Deferred Income Tax(4.33M)(6.26M)(3.24M)15.99M(9.34M)
Stock-Based Compensation1.43M4.02M1.64M5.05M5.27M
Change in Working Capital(29.66M)20.04M17.87M(54K)(12.68M)
Accounts Receivables(16.65M)10.41M801K(5.83M)134K
Inventory(6.93M)(3.22M)12.72M1.57M(3.25M)
Accounts Payables210K3.17M7.16M3.69M(9.05M)
Other Working Capital(6.28M)9.69M(2.81M)515K(515K)
Other Non-Cash Items14.56M88.43M25.25M1.87M(10.67M)
Operating Cash Flow(49.63M)(2.48M)8.21M16.78M25.89M
Capital Expenditures(378K)(9.19M)(1.6M)(2.76M)(2.52M)
Acquisitions (Net)7.47M10.3M0054K
Purchases of Investments(900K)(10.37M)000
Sales of Investments10.24M71K0100K0
Other Investing Activities897K10.37M47K2.22M0
Investing Cash Flow17.33M1.18M(1.56M)(445K)(2.46M)
Debt Repayment29.71M(6.76M)(8.39M)(14.48M)(8.36M)
Common Stock Issued44.94M7.94M3.13M1.5M976K
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(4.39M)7.94M(431K)(612K)(2.42M)
Financing Cash Flow26.4M1.18M(5.69M)(13.59M)(9.81M)
Effect of Forex Changes00000
Net Change in Cash(5.9M)(118K)972K2.75M13.62M
Free Cash Flow(50.01M)(11.67M)6.61M14.02M23.37M

Auxly Cannabis Group Inc.

TSX:XLY.TO

Intrinsic Alpha fair value

Locked

Current Price

$3.53

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.